Form 4 for NAMS NewAmsterdam Pharma Co N.V.
Accepted 2025-03-28 00:00:00 ET · period of report 2025-03-26 · accession 0000950170-25-046958 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-28 | 2025-03-26 | NAMS | LANGE LOUIS G | Dir | M - OptEx | $0.00 | +3,102 | 10.1K | +45% | $0 |
| D | 2025-03-28 | 2025-03-26 | NAMS | LANGE LOUIS G | Dir | A - Grant | — | +3,308 | 3,308 | New | — |
| D | 2025-03-28 | 2025-03-26 | NAMS | LANGE LOUIS G | Dir | M - OptEx | — | -3,102 | 206 | -94% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2025-03-26 | M | A | 3,102 | $0.00 | 10,062 | D | — | — | |
| 2 | Derivative | Restricted Stock Unit | 2025-03-26 | A | A | 3,308 | — | 3,308 | D | — · — to — | 3,308 Ordinary Shares | (F3) The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the "BCA"). The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date. (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share. (F2) Upon grant, 3,102 RSUs were fully-vested. The remaining RSUs will vest as follows, subject to the Reporting Person's continued service with the Company as of each of the applicable vesting dates: 69 of the remaining RSUs will vest on April 1, 2025; 69 of the remaining RSUs will vest on May 1, 2025; and 68 of the remaining RSUs will vest on June 1, 2025. |
| 3 | Derivative | Restricted Stock Unit | 2025-03-26 | M | D | 3,102 | — | 206 | D | — · — to — | 3,102 Ordinary Shares | (F3) The RSUs were granted on March 26, 2025 as earnout RSUs pursuant to the business combination agreement, dated as of July 25, 2022, by and among the issuer, Frazier Lifesicences Acquisition Corporation, NewAmsterdam Pharma Holding B.V., and NewAmsterdam Pharma Investment Corporation (the "BCA"). The BCA provided that certain optionholders would receive RSUs of the issuer, determined in accordance with a formula set forth in the BCA and for no additional consideration, if a certain clinical development milestone was achieved within five years of the Closing Date. The Reporting Person's right to receive the earnout RSUs became fixed and irrevocable on the Closing Date. (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share. (F2) Upon grant, 3,102 RSUs were fully-vested. The remaining RSUs will vest as follows, subject to the Reporting Person's continued service with the Company as of each of the applicable vesting dates: 69 of the remaining RSUs will vest on April 1, 2025; 69 of the remaining RSUs will vest on May 1, 2025; and 68 of the remaining RSUs will vest on June 1, 2025. |